Inflarx NV (IFRX) NPV

Sell:$2.27Buy:$2.32$0.05 (2.23%)

NASDAQ:0.19%
Prices delayed by at least 15 minutes
Sell:$2.27
Buy:$2.32
Change:$0.05 (2.23%)
Deal now
Prices delayed by at least 15 minutes
Sell:$2.27
Buy:$2.32
Change:$0.05 (2.23%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

Key people

Niels C. Riedemann
Chief Executive Officer, Executive Director
Thomas Taapken
Chief Financial Officer
Derval O'Carroll
Senior Vice President, Global Head of Regulatory Affairs and Compliance
Renfeng Guo
Chief Scientific Officer, Executive Director
Camilla Chong
Chief Medical Officer
Nicolas Fulpius
Independent Chairman of the Board
Richard Brudnick
Non-Executive Independent Director
Anthony Gibney
Non-Executive Independent Director
Hege Hellstrom
Non-Executive Independent Director
Mark Kubler
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Germany
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    NL0012661870
  • Market cap
    $132.49m
  • Employees
    66
  • Shares in issue
    58.88m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.